濮阳东方妇科医院做人流值得信赖(濮阳东方妇科在线免费咨询) (今日更新中)

SHANGHAI, Jan. 29 (Xinhua) -- Three Carrefour stores were fined 500,000 yuan (75,988 U.S. dollars) each on Saturday for overcharging customers in east China's metropolitan Shanghai, said municipal price regulators.The fine is the highest for such wrongdoing, with the tickets being issued Saturday morning.The three stores were also ordered to correct their illegal pricing and refund overcharged customers, said the regulators.A hearing will be held to decide the final amount of the fine. Carrefour representatives will be able to respond to the charges at the hearing, according to regulators.China's price regulator announced last week that it had found several retailers cheating customers, which included 11 of Carrefour's China stores.Carrefour China promised customers Saturday that it would provide refunds of five times the difference between advertised prices and incorrect prices charged at registers, after it was blacklisted by Chinese authorities due to deceptive pricing.Chen Bo, spokesperson with Carrefour China, apologized to Chinese customers during an exclusive interview with Xinhua.Chen said the company has started to work on this pricing issue.Carrefour China has established both short-term and long-term measures to resolve the issue, Chen added."We will have our special control group conduct internal price inspections, with wide coverage and high frequency," Chen said.Chen said the refund policy would be permanently implemented at Carrefour's 182 outlets in China, with non-implementation of the policy being regarded as a violation of company rules.The National Development and Reform Commission, China's top economic planner, also urged authorities to step up price checks ahead of the Spring Festival, which falls on Feb. 3 this year.The Spring Festival holiday is usually the busiest shopping season, as the public makes large purchases of food and gifts for families and friends.

WASHINGTON, April 25 (Xinhua) -- Study by scientists at the Rockefeller University shows that anti-inflammatory drugs reduce the effectiveness of the most widely used class of antidepressant medications, the selective serotonin reuptake inhibitors (SSRIs), taken for depression and obsessive-compulsive disorder and anxiety disorders.This discovery, published online Monday in the Proceedings of the National Academy of Sciences, may explain why so many depressed patients taking SSRIs do not respond to antidepressant treatment and suggests that this lack of effectiveness may be preventable.The study may be especially significant in the case of Alzheimer's disease. Such patients commonly suffer from depression and unless this can be treated successfully, the course of the illness is likely to be more severe. Depression in the elderly is also a risk factor for developing Alzheimer's Disease and researchers have suggested that treating depression in the elderly might reduce the risk of developing the disease.In the recent study, investigators treated mice with antidepressants in the presence or absence of anti-inflammatory drugs. They then examined how the mice behaved in tasks that are sensitive to antidepressant treatment. They found that the mice's behavioral responses to antidepressants were inhibited by anti- inflammatory/analgesic treatments.They then confirmed these effects in a human population. Depressed individuals who reported anti-inflammatory drug use were much less likely to have their symptoms relieved by an antidepressant than depressed patients who reported no anti- inflammatory drug use. The effect was rather dramatic since, in the absence of any anti-inflammatory or analgesic use, 54 percent of patients responded to the antidepressant, whereas success rates dropped to approximately 40 percent for those who reported using anti-inflammatory agents."Many elderly individuals suffering from depression also have arthritic or related diseases and as a consequence are taking both antidepressant and anti-inflammatory medications. Our results suggest that physicians should carefully balance the advantages and disadvantages of continuing anti-inflammatory therapy in patients being treated with antidepressant medications," leader author Paul Greengard said.

SYDNEY, May 27 (Xinhua) -- A toddler and a policeman have become the latest victims of a rare and potentially deadly mosquito-borne disease in Western Australia (WA), local media reported on Friday.The two-year-old child contracted Murray Valley encephalitis (MVE) in the Kimberley of WA and is now in Royal Darwin Hospital in a stable condition, according to Australian Associated Press (AAP).The 29-year-old police officer, who was recently contracted the disease at an Aboriginal community of WA, has emerged from a coma in a Perth hospital but is still unable to communicate.It is not known if the victims from WA's far north will fully recover.In April 2011, a man who had been traveling in WA's northwest became the first person in the state to die from the disease in three years.A 19-year-old Canadian tourist also died after contracting MVE while traveling through the Northern Territory earlier in May.A WA Health Department spokeswoman said nine West Australians had contracted MVE so far in 2011. Several people remain very ill in hospital, she said.

BEIJING, May 21 (Xinhua) -- China's State Food and Drug Administration (SFDA) issued a circular on Friday banning the use of Nimesulide, an anti-inflammatory drug, for children under the age of 12, considering potential side-effects such as liver and kidney damage.Nimesulide is a non-steroidal anti-inflammatory drug that first became available in Italy in 1985. It is now used in more than 50 countries and regions.The drug entered Chinese markets in 1997.According to the SFDA, while common adverse reactions to the drug include vomiting and stomache, domestic and overseas statistics indicate that more severe issues are related to the drug, such as blood coagulation disorders, decreased white blood cells and damage to liver and kidney.Previously, the SFDA only prevented the use of the drug among children one year old or younger.Also on Friday, the SFDA ordered the suspension of the production, sales and use of Duxil (almitrine and raubasine compound) due to its "unobvious" efficacy.According to the SFDA, clinical research found "little" evidence proving the drug effectively improves the cognitive ability for patients suffering vascular cognitive impairment.The drug was supposed to treat symptoms related to cognition and sensory nerve damage.The moves came after a two-month nationwide campaign was launched earlier this month to probe the quality of essential drugs and ensure drug safety.Official figures show that China's National Center for Adverse Drug Reaction Monitoring received 692,904 reports of adverse reactions in 2010, up 8.4 percent compared with those in 2009.Among the total, 109,991 cases involved new or severe adverse reactions, a year-on-year increase of 16.2 percent.

WASHINGTON, Jan. 20 (Xinhua) -- Officials from China and the United States on Thursday signed a new agreement to support panda breeding, research and conservation efforts by the two countries, an exciting news for numerous American fans of the cute animals.Zang Chunlin, Secretary General of the China Wildlife Conservation Association, and Dennis Kelly, Director of the U.S. Smithsonian's National Zoo, signed the Giant Panda Cooperative Research and Breeding Agreement.Under the agreement, a pair of giant pandas, Mei Xiang and Tian Tian, will remain at the National Zoo in Washington D.C. for five more years.Also in attendance at the signing ceremony at the National Zoo was Chen Naiqing, wife of China's Ambassador to the U.S. Zhang Yesui, U.S. Secretary of the Interior Ken Salazar and Mary Kaye Huntsman, wife of U.S. Ambassador to China Jon Huntsman.On behalf of the Chinese embassy and Ambassador Zhang, Chen expressed appreciation to the National Zoo for taking care of these giant pandas and to all American people for their love for them."Although the weather is cold today, the friendship between our people keeps us warm," she said. "I am confident that through joint efforts, our cooperation will grow, our friendship will deepen, and the future will be even brighter."The first two years of the new agreement, effective immediately through Dec. 5, 2015, include a cooperative study involving reproductive experts from the China Conservation and Research Center for the Giant Panda in Wolong and the Smithsonian's Conservation Biology Institute to oversee the breeding of Mei Xiang and Tian Tian."I am proud that this agreement not only ensures that visitors to the zoo will continue to be able to visit and learn about these beautiful animals, but also provides a strong platform for improving the conservation of wild pandas and their habitat in China," said Salazar.He said those giant pandas have "long symbolized the close partnership the United States has with China as we work together to conserve and recover one of the world's most endangered species in the wild."Mei Xiang and Tian Tian have lived at the Smithsonian's National Zoo since Dec. 6, 2000. Both pandas were born in Wolong, China and had parents that were wild born. Mei Xiang, which means "beautiful fragrance," will turn 13 on July 22 and Tian Tian, meaning "more and more," will turn 14 on Aug. 27.The current pair has not produced a cub since 2005, when Tai Shan, a male, was born. Tai Shan went back to China in February, 2010.

来源：资阳报